Company intelligence / Profile preview

Capricor Therapeutics

San Diego, California, United Statescapricor.com ↗

Ownership: Public · CAPR
Development stage: Phase 3

Overview

Lead candidate deramiocel (CAP-1002) is currently in Phase 3 clinical development for treating Duchenne muscular dystrophy. The FDA has accepted and granted Priority Review for deramiocel, with potential approval by September 2026. The drug has received Orphan Drug Designation from both FDA and EMA, as well as RMAT designation in the US and ATMP designation in Europe[8].

Therapeutic areas: Rare DiseasesInfectious Diseases
Modalities: Cell therapyExosome-based therapeutics
Industry: Biotech

Drug pipeline

10 assets

deramiocel

9 more assets in the full pipeline.

Partnerships

Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.)National Institute of Allergy

Financials

Market cap: $498M
Total revenue: $0
Enterprise value: $351.2M

Beyond the preview

Go deeper on Capricor Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Capricor Therapeutics.